Spinout Active LTD

Company profile

Oxford Nanoimaging Limited

Super Resolution Microscopy | ONI

Oxford Nanoimaging Limited is a UK company with status active founded in 2016 based in South East England.

CRN
10023177
Founded
2016
Age
10

Overview

Browse spinouts
Legal name
OXFORD NANOIMAGING LIMITED
Region
South East England
Registered address
LINACRE HOUSE JORDAN HILL BUSINESS PARK
BANBURY ROAD
OXFORD
ENGLAND
OX2 8TA
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active LTD
Oxford Nanoimaging Limited
CRN 10023177
2
Direct and ultimate controller Active PLC

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
-£9,585,327
Employees
52

Company events

Reference milestones and recent Companies House filing stream events.

5 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

14 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

24 Feb
2016

Incorporated

Inception

Company registered at Companies House

Spinout profile

2 entries

Company description

Making, marketing and supporting super-resolution fluorescence microscopes

Oxford Nanoimaging designs, develops, and manufactures super-resolution microscopes.

Project impact

Has supplied microscopes to fuel basic and applied research in the microbiology, DNA nanotechnology, biochemistry and biotechnology sectors at several labs worldwide.

Oxford Nanoimaging
2016
Oxford Nanoimaging
2016

Public funding

1 award
First funded
2020
Funded years
2020
Age at first award
4 years

Projects

2020 Collaborative R&D Lead participant

ONI-CoV2RNA: A single step imaging-based assay for direct detection of SARS-CoV-2 RNA

1 Oct 2020 to 31 Dec 2021

Awarded
£110,795
Total cost £380,999

Diagnostic testing for SARS-CoV2 is at the centre of the public health response to the COVID-19 pandemic, facilitating the isolation of asymptomatic cases thereby suppressing community transmission. COVID-19 testing is becoming ever more widespread as economic and recreational activities resume, for example, a negative test result is now required to trave...

Product types

Collaborative R&D